Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study

OBJECTIVE: Several biological DMARDs (bDMARDs) have demonstrated anti-inflammatory effects in PsA. However, their comparative cardiovascular safety profiles remain unknown. We evaluated the risk of major adverse cardiovascular events (MACEs) in PsA patients on therapy with different classes of bDMAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Pina Vegas, Laura, Le Corvoisier, Philippe, Penso, Laetitia, Paul, Muriel, Sbidian, Emilie, Claudepierre, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996783/
https://www.ncbi.nlm.nih.gov/pubmed/34244706
http://dx.doi.org/10.1093/rheumatology/keab522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996783/
https://www.ncbi.nlm.nih.gov/pubmed/34244706
http://dx.doi.org/10.1093/rheumatology/keab522

Ejemplares similares